Cargando…
Predictors of dronedarone plasma drug concentrations and effect on atrial fibrillation/atrial flutter recurrence: Analyses from the EURIDIS and ADONIS studies
BACKGROUND: In this post hoc analysis, we assessed patient characteristics as predictors of dronedarone trough concentrations and characterized the relationship of trough concentrations of dronedarone with its efficacy and safety. HYPOTHESIS: Dronedarone is recommended as a 400 mg twice daily dose t...
Autores principales: | Thind, Munveer, McKindley, David S., Reiffel, James A., Naccarelli, Gerald V., Stewart, John, Kowey, Peter R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799059/ https://www.ncbi.nlm.nih.gov/pubmed/35032136 http://dx.doi.org/10.1002/clc.23768 |
Ejemplares similares
-
Dronedarone treatment following cardioversion in patients with atrial fibrillation/flutter: A post hoc analysis of the EURIDIS and ADONIS trials
por: Thind, Munveer, et al.
Publicado: (2020) -
Efficacy and safety of dronedarone versus placebo in patients with atrial fibrillation stratified according to renal function: Post hoc analyses of the EURIDIS‐ADONIS trials
por: Thind, Munveer, et al.
Publicado: (2022) -
The Role of Dronedarone in the Treatment of Atrial Fibrillation/Flutter in the Aftermath of PALLAS
por: Naccarelli, Gerald V, et al.
Publicado: (2014) -
Dronedarone for the treatment of atrial fibrillation and atrial flutter: approval and efficacy
por: Wolbrette, Deborah, et al.
Publicado: (2010) -
Effect of dronedarone vs. placebo on atrial fibrillation progression: a post hoc analysis from ATHENA trial
por: Blomström-Lundqvist, Carina, et al.
Publicado: (2023)